Tech Company Financing Transactions
Ascentage Pharma Funding Round
Ascentage Pharma, based in Jiangsu, secured $150 million in funding from Oriza Ventures, YuanMing Capital and ArrowMark Partners.
Transaction Overview
Company Name
Announced On
7/18/2018
Transaction Type
Venture Equity
Amount
$150,000,000
Round
Series C
Investors
Oriza Ventures (Lead Investor)
YuanMing Capital (Lead Investor)
Proceeds Purpose
Funding to support broad and innovative product pipeline of apoptosis-targeted candidates and build-out of state-of-the-art R&D centers and manufacturing facilities.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
218 Xinghu St. Building B7 7th Floor Suzhou Industrial Park
Jiangsu, 215000
USA
Jiangsu, 215000
USA
Phone
Website
Email Address
Overview
Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Dajun Yang
Chief Medical Officer
Yifan Zhai
Chief Scientific Officer
Shaomeng Wang
General Manager
Ming Guo
Browse more venture capital transactions:
Prev: 7/18/2018: Blast venture capital transaction
Next: 7/18/2018: PeerSpace venture capital transaction
Share this article
Where The Data Comes From
We document every notable VC transaction. VC transactions reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs